Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02303431 · ClinicalTrials.gov registry record · Phase 1
Phase 1 Pediatric Pharmacokinetics/Pharmacodynamics (PK/PD) Study
A Phase 1 study of Venous Thromboembolism and Deep Vein Thrombosis, sponsored by Daiichi Sankyo.
- Completed
- Registry status
- Phase 1
- Development phase
- 66
- Enrollment target
- 20
- Study locations
NCT02303431 is a Phase 1 study of Venous Thromboembolism and Deep Vein Thrombosis that has completed, run by Daiichi Sankyo. The registered enrollment target is 66 participants, below the 6,295-participant average among 47 other Venous Thromboembolism trials with a reported enrollment target (99% lower). The trial reports 20 study locations across 13 states.
The verdict
NCT02303431, a Phase 1 study of Venous Thromboembolism and Deep Vein Thrombosis, has completed, sponsored by Daiichi Sankyo.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 66 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is the first evaluation of edoxaban in pediatric subjects. In this Phase 1 study, a single dose of edoxaban will be given to pediatric subjects who require anticoagulant therapy to see what the body does to the drug (pharmacokinetics) and what the drug does to the body (pharmacodynamics), and to compare if these effects are similar to those observed in adults.
Conditions Studied
Interventions
- DRUG Edoxaban low dose
- DRUG Edoxaban high dose
Study Locations (20)
Other
- Childrens Hospital of Eastern Ontario - Ottawa
- Hopital Arnaud de Villeneuve - Montpellier
- CHU Bordeaux - Hopital Haut-Leveque - Pessac
- Nirmal Hospital Pvt. Ltd - Gujrāt
- Institute of Child Health - Kolkata
- Christian Medical College and Hospital - Ludhiāna
- Istituto Giannina Gaslini - UOSD Emostasi e Trombosi - Genova
California
- University of California, Los Angeles (UCLA) - Los Angeles
- Lucile Packard Children's Hospital Stanford University - Palo Alto
Colorado
- University of Colorado Denver - Denver
Illinois
- Ann and Robert H. Lurie Children's Hospital of Chicago - Chicago
Indiana
- Indiana Hemophilia and Thrombosis Center - Indianapolis
Kentucky
- University of Louisville ; Kosair Charities Pediatric Clincial Research Unit - Louisville
North Carolina
- Duke University Medical Center (DUMC) - Durham
Ohio
- University Hospitals Case Medical Center - Rainbow Babies and Children's Hospital - Cleveland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 66 participants |
| Start Date | 2014-11-05 |
| Est. Completion | 2021-09-16 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02303431
The ClinicalTrials.gov registry entry for NCT02303431 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 66 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 6,295-participant average among 47 other Venous Thromboembolism trials with a reported enrollment target (99% lower). The listed sponsor is Daiichi Sankyo, which has 236 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Venous Thromboembolism appearing as the primary indexed condition, and to 2 interventions - of which Edoxaban low dose is the first listed.
NCT02303431 reports 20 study locations spanning 13 distinct geographic areas - top geographies include Other, California, Colorado.
Frequently Asked Questions
What is clinical trial NCT02303431 about?
NCT02303431 is a clinical study titled "Phase 1 Pediatric Pharmacokinetics/Pharmacodynamics (PK/PD) Study". This is the first evaluation of edoxaban in pediatric subjects. In this Phase 1 study, a single dose of edoxaban will be given to pediatric subjects who require anticoagulant therapy to see what the body does to the drug (pharmacokinetics) and what the drug does to the body (pharmacodynamics), and t...
What is the current status of trial NCT02303431?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 66 participants. The study started on 2014-11-05. Estimated completion is 2021-09-16.
What conditions does trial NCT02303431 study?
This clinical trial studies the following conditions: Venous Thromboembolism, Deep Vein Thrombosis.
What interventions are being tested in trial NCT02303431?
The interventions under investigation include: Edoxaban low dose (DRUG), Edoxaban high dose (DRUG).
Who is sponsoring clinical trial NCT02303431?
This trial is sponsored by Daiichi Sankyo, which has 236 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02303431 being conducted?
This trial has 20 study locations across California, Colorado, Illinois, Indiana, Kentucky. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Venous Thromboembolism
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Twice Daily Enoxaparin Prophylaxis in Reconstructive Surgery Patients
COMPLETED · Phase 1
-
Glioblastoma Remote Monitoring and Care - Research Protocol
RECRUITING · NA
-
Venous Thromboembolism Prevention in Outpatients With Glioma
RECRUITING · Phase 2
-
PRospective Evaluation of Peripartum Anticoagulation ManaGement for ThrOmboembolism
RECRUITING
-
Intervention to Improve Utilization of Extended Venous Thromboembolism Prophylaxis After Cancer Surgery
RECRUITING · NA
-
Computerized Registry of Patients With Venous Thromboembolism (RIETE)
RECRUITING
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.